Harrow, Inc. Enters Material Definitive Agreement
Ticker: HROW · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1360214
| Field | Detail |
|---|---|
| Company | Harrow, INC. (HROW) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $40,000,000, $20,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, debt
Related Tickers: HROW
TL;DR
Harrow Inc. signed a big deal, expect financial moves.
AI Summary
On September 26, 2025, Harrow, Inc. entered into a material definitive agreement related to its financial obligations. The company, previously known as Harrow Health, Inc., is involved in the pharmaceutical preparations industry and is incorporated in Delaware.
Why It Matters
This filing indicates a significant new agreement for Harrow, Inc., which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can introduce new financial obligations or strategic shifts that carry inherent risks.
Key Numbers
- 8.625% — Senior Notes Due 2026 (Indicates a specific debt instrument of the company.)
- 11.875% — Senior Notes Due 2027 (Indicates another specific debt instrument of the company.)
Key Players & Entities
- HARROW, INC. (company) — Filer
- Harrow Health, Inc. (company) — Former Company Name
- Imprimis Pharmaceuticals, Inc. (company) — Former Company Name
- TRANSDEL PHARMACEUTICALS INC (company) — Former Company Name
- September 26, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Harrow, Inc. on September 26, 2025?
The filing states that Harrow, Inc. entered into a material definitive agreement, and it is also listed under 'Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant', suggesting it involves financial commitments.
What are the specific financial obligations mentioned in the filing?
The filing references 'HROW:Sec8.625SeniorNotesDue2026Member' and 'HROW:Sec11.875SeniorNotesDue2027Member', indicating existing senior notes with specific interest rates and maturity dates.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on September 26, 2025.
What was Harrow, Inc. formerly known as?
Harrow, Inc. was formerly known as Harrow Health, Inc., Imprimis Pharmaceuticals, Inc., and TRANSDEL PHARMACEUTICALS INC.
What industry does Harrow, Inc. operate in?
Harrow, Inc. operates in the Pharmaceutical Preparations industry, with a Standard Industrial Classification code of 2834.
Filing Stats: 844 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2025-09-29 07:00:47
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HROW The Nasdaq
- $40,000,000 — lity in the initial principal amount of $40,000,000, together with an uncommitted increment
- $20,000,000 — credit in the principal amount of up to $20,000,000. The New Credit Agreement will mature o
Filing Documents
- form8-k.htm (8-K) — 47KB
- 0001493152-25-015878.txt ( ) — 258KB
- hrow-20250926.xsd (EX-101.SCH) — 4KB
- hrow-20250926_def.xml (EX-101.DEF) — 26KB
- hrow-20250926_lab.xml (EX-101.LAB) — 36KB
- hrow-20250926_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARROW, INC. Dated: September 29, 2025 By: /s/ Andrew R. Boll Andrew R. Boll President and Chief Financial Officer